AbbVie

This weekend's Barron's cover story presents the findings of the latest Energy Roundtable. Other featured articles examine the prospects for a tech giant's quantum computing efforts and an industry leader with little to fear from Amazon. Also, Warren Buffett's latest annual...

Benzinga has featured a look at many investor favorite stocks over the past week. Bullish calls featured a top biotech, an online payment company and an energy infrastructure giant. Bearish calls included a leading coffee chain, REITs and a hotel operator in the news. Volatility came...

This weekend's Barron's cover story features the second part of the 2018 Barron's Roundtable feature. Each Roundtable panelist offers up a handful of recommendations and reasons why they like these particular picks now. Other featured articles include an investor's guide...

The preliminary success of a drug designed to combat idiopathic pulmonary fibrosis could give Galapagos NV (ADR) (NASDAQ: GLPG) a 10-percent boost, according to Morgan Stanley. A 23-person study of the drug GLPG1690, an autotaxin inhibitor, found that patients had better lung function than those...

Three leading biotech companies will step into the earnings spotlight this week. Consensus forecasts from Wall Street analysts call for earnings growth from just two of them. And only one of them has topped estimates by double-digits in recent quarters. While the biotechnology industry has had a...

The three largest biotechs are set to share their latest quarterly results this week. Wall Street analysts are looking for solid to strong growth from all three. However, expectations are lower for many other biotech and pharmaceutical companies reporting this week. The three largest public...

Two of the so-called FANG stocks offered up disappointing quarterly results last week. The other two FANG stocks are on deck to share their latest results this week. Wall Street analysts continue to look for strong earnings growth from both of them. The so-called FANG stocks were the momentum...

Upcoming earnings highlights include the latest results from two automaker giants. Wall Street analysts are looking for strong earnings growth from both of them. However, estimates have been slipping for one and rising for the other. Expectations were already high for the latest earnings from...

Shares of AbbVie Inc (NYSE: ABBV) were trading higher by nearly 2 percent early Tuesday morning after the company announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval of Venclexta. Venclexta, a table taken orally, is used for the treatment of patients diagnosed...

Shares of AbbVie Inc (NYSE: ABBV) were trading lower by more than 4 percent early Friday morning after the company reported its fourth quarter results. AbbVie earned $1.13 per share in the fourth quarter on revenue of $6.36 billion. Wall Street analysts were expecting the company to earn $1.12...